Immunotherapy for stage 4 prostate cancer is revolutionizing the way advanced disease is being treated, offering hope for patients worldwide. Unlike conventional treatment methods such as surgery and ...

Immunotherapies use the power of your immune system to fight your cancer. Vaccines are one form of immunotherapy. Sipuleucel-T is a vaccine used for advanced, metastatic prostate cancer if: It no ...

A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer. Researchers from the University of Sheffield have ...

PHOENIX — A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may ...

Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy can improve results when added to a radiotherapy-based treatment regimen for ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

Share on Pinterest A study in mice investigates the potential of an immunotherapy-dietary supplement combo in treating prostate cancer. Image credit: Don Wu/Getty Images. About 13% of cisgender men ...

In December, the share price of Candel Therapeutics surged by more than 200% when the company revealed the success of a phase 3 trial of its multimodal biological immunotherapy CAN-2409 (aglatimagene ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. Black men with ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That connection is ...

FORT LAUDERDALE, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Syncromune ®, Inc., a clinical-stage biopharmaceutical company advancing SYNC-T™, an investigational platform combination immunotherapy for ...